Nivolumab is a medication used in this trial to help the immune system fight cancer. It works by blocking a protein that stops the immune system from attacking cancer cells. The trial aims to find the best dose of nivolumab for patients who have shown a complete, partial, or stable response to previous treatments. The goal is to ensure that the medication maintains its effectiveness even when the dose is reduced.

Melanoma – Melanoma is a type of skin cancer that begins in the melanocytes, which are the cells responsible for producing melanin, the pigment that gives skin its color. It often appears as a new mole or a change in an existing mole, and it can be identified by its irregular shape, multiple colors, or larger size. Melanoma can spread to other parts of the body if not detected early. It is more common in individuals with fair skin, a history of sunburns, or a family history of the disease. The progression of melanoma can vary, with some cases remaining localized while others may metastasize. Early detection and monitoring of skin changes are crucial in managing this condition.

Renal Cell Carcinoma – Renal cell carcinoma is a type of kidney cancer that originates in the lining of the small tubes within the kidney. It is the most common type of kidney cancer in adults and often does not cause symptoms in its early stages. As it progresses, it may lead to symptoms such as blood in the urine, a lump in the abdomen, or unexplained weight loss. The disease can spread to other organs if not treated, but it typically grows slowly. Risk factors include smoking, obesity, and high blood pressure. Understanding the progression of renal cell carcinoma is important for managing the disease effectively.